Correction To: Neutropenia Management With Palbociclib in Japanese Patients With Advanced Breast Cancer

Breast Cancer - Japan
doi 10.1007/s12282-019-00984-1
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Palbociclib Has No Clinically Relevant Effect on the QTc Interval in Patients With Advanced Breast Cancer

Anti-Cancer Drugs
Cancer ResearchOncologyPharmacology
2018English

Barriers to Treatment in Patients With Locally Advanced Breast Cancer

Journal of the National Comprehensive Cancer Network : JNCCN
MedicineOncology
2013English

Incidence and Risk of Severe Neutropenia in Advanced Cancer Patients Treated With Cetuximab

Drugs in R and D
Pharmacology
2011English

T-Dm1 Aids Patients With Advanced Breast Cancer

Cancer Discovery
Oncology
2013English

Palbociclib With Letrozole in Postmenopausal Women With ER+/HER2− Advanced Breast Cancer: Hematologic Safety Analysis of the Randomized PALOMA‐2 Trial

Oncologist
Cancer ResearchMedicineOncology
2019English

P2.01-35 Predicting Risk of Chemotherapy-Induced Severe Neutropenia in Patients With Advanced Lung Cancer

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Canadian Supportive Care Recommendations for the Management of Neutropenia in Patients With Cancer

Current Oncology
Oncology
2008English

Palbociclib: First CDK4/6 Inhibitor in Clinical Practice for the Treatment of Advanced HR-Positive Breast Cancer

Breast Care
SurgeryOncology
2016English

Feasibility of Breast Conserving Surgery in Locally Advanced Breast Cancer Patients Treated With Neoaduvant Therapy

Juniper Online Journal of Case Studies
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy